"Plasma Phosphorylated Tau 217 Immunoassay: A Breakthrough in Early Alzheimer's Detection"
A cohort study evaluated the diagnostic accuracy of a commercially available plasma phosphorylated tau 217 (p-tau217) immunoassay for Alzheimer disease (AD) pathology. The study found that the p-tau217 immunoassay accurately identified abnormal amyloid β (Aβ) and tau pathologies, showing similar accuracies to cerebrospinal fluid biomarkers. Longitudinally, plasma p-tau217 values showed an annual increase only in Aβ-positive individuals, with the highest increase observed in those with tau positivity. The wider availability of high-performing assays may expedite the use of blood biomarkers in clinical settings and benefit the research community.